Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine maintenance in acute myeloid leukemia after induction response
2010-020432-18Phase 2Completed
- Sponsor
- Asociación Andaluza de Hematología y Hemoterapia
- Start
- Feb 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine in acute myeloid leukemia (AML), sponsored by Asociación Andaluza de Hematología y Hemoterapia. Primary endpoints: Response rate by IWG 2003 criteria and Progression-free time. Started Feb 2011; status: completed.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-020432-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-020432-18.